Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]

First Posted Date: 2012-01-27

Last Posted Date: 2016-04-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 150

Registration Number: NCT01519921

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Phase 3

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]

First Posted Date: 2012-01-27

Last Posted Date: 2022-11-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 165

Registration Number: NCT01519960

Locations: 🇺🇸
Johns Hopkins Hospital - Pediatric Gastroenterology, Baltimore, Maryland, United States
🇺🇸
Children's Hospital Boston-Harvard Medical School; Division of Gastoenterology, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

and more 36 locations

A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis

Phase 4

Completed

Conditions: Anemia, Kidney Disease, Chronic

Interventions: Drug: Methoxy polyethylene glycol-epoetin beta

First Posted Date: 2012-01-27

Last Posted Date: 2019-06-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 87

Registration Number: NCT01519947

Locations: 🇲🇽
Unidad De Dialisis La Loma S.C., Pureto Vallarta, Mexico
🇲🇽
Clínica San Cosme Centro Especializado en el Tratamiento de Enfermedades Renales S.C, Aguascalientes, Mexico
🇲🇽
Nefros Investigación S.C., Delegación Coyoacan, Mexico

and more 4 locations

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Phase 1

Terminated

Conditions: Malignant Melanoma

Interventions: Drug: vemurafenib

First Posted Date: 2012-01-26

Last Posted Date: 2016-10-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6

Registration Number: NCT01519323

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: danoprevir
Drug: darunavir
Drug: ritonavir

First Posted Date: 2012-01-26

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT01519336

A Study of RO4917523 in Patients With Fragile X Syndrome

Phase 2

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: RO4917523 0.5 mg
Drug: RO4917523 1.5 mg
Drug: Placebo

First Posted Date: 2012-01-25

Last Posted Date: 2016-07-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 185

Registration Number: NCT01517698

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Phase 3

Completed

Conditions: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)

Interventions: Other: Background care
Drug: Placebo
Drug: dalcetrapib

First Posted Date: 2012-01-25

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2220

Registration Number: NCT01516541

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Phase 2

Terminated

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: RO6807952
Drug: liraglutide
Drug: Placebo

First Posted Date: 2012-01-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT01516476

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: cyclosporine
Drug: danoprevir
Drug: ritonavir

First Posted Date: 2012-01-23

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 18

Registration Number: NCT01514968

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: trastuzumab emtansine

First Posted Date: 2012-01-20

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT01513083

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy